News
Health Canada approves Humira for inducing and maintaining clinical remission in pediatric patients ulcerative colitis. - AbbVie
AbbVie has announced that Health Canada has approved Humira (adalimumab) for inducing and maintaining clinical remission in pediatric patients five years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy including corticosteroids and/or azathioprine or 6- mercaptopurine or who are intolerant to such therapies.
With this approval, Humira offers pediatric patients with moderately to severely active ulcerative colitis the first subcutaneous antiTNF therapeutic option.
Condition: Ulcerative Colitis
Type: drug
90 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.